Recent advances in the treatment of disorders of the nervous system using interferon-α;Actualizacion del tratamiento con interferon alfa en las enfermedades del sistema nervioso

Revista de Neurologia

Volumn 29, Issue 12, 1999, Pages 1225-1235

  Cabrera Gomez J A ^a   Lopez Saura P ^b  

^a Hospital Dr Gustavo Aldereguia   (Cuba)

^b NONE

Author keywords

Disorders of the Central Nervous System; Disorders of the neuromuscular junction; Disorders of the peripheral nervous system; Interferon ; Interferon ; Interferons Interferon ; Leukocytic interferon ; Muscle disorders; Recombinant interferon 2(b)

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON;

ALLERGIC DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CENTRAL NERVOUS SYSTEM TUMOR; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; EPILEPSY; HERPES ZOSTER; HUMAN; PRION DISEASE; RABIES; REVIEW; REYE SYNDROME;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; INTERFERON-ALPHA;

EID: 0033576364     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.2912.98318     Document Type: Review

References (143)

1. Isaacs A, Lindenmann J. Virus interferon. I. The interferon. Proc R Soc Lond (Biol) 1957; 147: 258-67.
2. López Saura P. What is interferon good for? Biotecnología Aplicada 1992; 9: 207-27.
3. Cantell K, Pulkkinen E, Elouso R, Suominen J. Effect of interferon on severe psychiatric diseases. Ann Clin Res 1980; 12: 131-2.
4. Hardy KJ, Young HA. IFN gamma gene structure and regulation. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Klimpel GR, et al, eds. Interferon: principles and medical applications. Galveston, Tx: University Texas Med Branch; 1992. p. 47-64.
5. Zoon KC, Bekiz J, Millar D. Human interferon alpha family: protein structure and function. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Klimpel GR, et al, eds. Interferon: principles and medical applications. Galveston, Tx: University Texas Med Branch; 1992. p. 95-105.
6. Utsumi J, Shimizu H. Human interferon beta, protein structure and function. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Kumpel GR, et al, eds. Interferon: principles and medical applications. Galveston, Tx: University Texas Med Branch; 1992. p. 107-16.
7. Pestka S. The interferon receptors. Semin Oncol 1997; 24 (Suppl 9): S918-40.
8. Trotta PP, Nagabhusan TL. Gamma interferon. Protein structure and function. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Klimpel GR, et al, eds. Interferon: principles and medical applications. Galveston, Tx: University Texas Med Branch; 1992. p. 117-27.
9. Stuber D, Fountoulakis M, Garotta G. IFN gamma receptor: protein structure and function. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Klimpel GR, et al, eds. Interferon: principles and medical applications. Galveston: University Texas Med Branch; 1992. p. 139-50.
10. Levy DE. Cytoplasmatic events in signal transduction leading to IFN alpha induced gene expression. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Klimpel GR, et al, eds. Interferon: principles and medical applications. Galveston, Tx: University Texas Med Branch; 1992. p. 161-73.
11. Klein JB, Schepers TM, Dean WL, Sonnenfeld G, McLeish KR. Role of intracellular calcium concentration and protein kinase C activation in IFN gamma stimulation of U937 cells. J Immunol 1990; 144: 4305-11.
12. Gupta SL. Regulation of interferon-inducible genes. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Klimpel GR, et al, eds. Interferon: principles and medical applications. Galveston, Tx: University Texas Med Branch; 1992. p. 193-213.
13. Lew DJ, Decker T, Darnell JE Jr. Alpha interferon and gamma interferon stimulate transcription of a single gene through different signal transduction pathways. Molec Cell Biol 1989; 9: 540-4-11.
14. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of actions and use in multiple sclerosis. Ann Neurol 1995; 37: 7-15.
15. Fleishmann RW Jr, Fleishmann CN. Mechanisms of interferons antitumor actions. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Klimpel GR, et al, eds. Interferon: principles and medical applications. Galveston, Tx: University Texas Med Branch; 1992. p. 299-309.
16. Stewart VC, Giovannoni G, Land JM, Mc Donald WI, Clark JW, Heales SJR. Pretreatment of astrocytes with interferon-α/β impairs interferon gamma induction of nitric oxide synthase. J Neurochem 1997; 68: 2547-51.
17. Vial TH, Bailly F, Descotes J, Trepo C. Effets secondaires de l'interféron alpha. Gastroenterol Clin Biol 1996; 20: 462-89.
18. Kuriyama K, Hori T, Mori T, Nakashima T. Actions of interferon alpha on the activity of preoptic thermosensitive neurons in tissue slices. Brain Res 1988; 454: 361-7.
19. Farkkila MA, Livanainen MV, Roine, RO, Cantell K. Effect of interferon on the course of amyotrophic lateral sclerosis. ALS Rev 1986; 5: 38.
20. Meyers CA, Valentine AD. Neurological and psychiatric adverse effects of immunological therapy. Adverse effects. CNS drugs 1995; 3: 56-88.
21. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alpha therapy for leukemia. Neurology 1995; 45: 947-50.
22. Meyers CA, Scheibel R, Forman AD. Persistent neurotoxicity of systemically administered interferon alpha. Neurology 1991; 41: 672-6.
23. Battochi AP, Evoli A, Servidei S, Palmisani MT, Apollo F, Tenait P. Myasthenia gravis during interferon alpha therapy. Neurology 1995; 45: 382-3.
24. Mitsuyama Y, Hashiguchi H, Murayama T, Koono M, Nishi S. An autopsied case of interferon encephalopathy. Jpn J Psychiatry Neurol 1992; 46: 741-8.
25. Manesis EK, Petrou C, Brouzas D, Hakziyannis S. Optic tract neuropathy complicating law-dose interferon treatment. J Hepatol 1994; 21: 474-7.
26. Gastiniau DA, Habermann TM, Hermann RC. Severe neuropathy associated with low dose interferon alpha. Am J Med 1989; 87: 116.
27. Jaubert D, Hauteville D, Pelissier JF, Muzellec Y. Neuopathie périphérique au cours d'un traitement par interféron alpha. Press Med 1991; 20: 221-2.
28. Negoro K, Fukusako T, Morimatsu M, Liao CM. Acute axonal polyneuropathy during interferon alpha-2a therapy for chronic hepatitis C. Muscle Nerve 1994; 17: 1351-2.
29. Read SJ, Krauford DHG, Pender MP. Trigeminal sensory neuropathy induced by interferon alpha therapy. Aust NZ J Med 1995; 25: 54.
30. Arai H, Tanaka M, Otha K, Kojo T, Nijima K, Imaguari M. Symptomatic myopathy associated with interferon therapy for chronic hepatitis C. Lancet 1995; 345: 582.
31. Matsuya M, Abe T, Tosaka M, Yonezagua K, Ono A, Ikeda M. The first case of polymyositis associated with interferon therapy. Intern Med 1994; 33: 806-8.
32. Greenfeld SM, Harvey RS, Thompson RPH. Rhabdomyolisis after treatment with interferon alpha. Br Med J 1994; 309: 20-7.
33. Quilichini R, Mazzerbo F, Baume D, Amiel O, Lafeuillade A, Pellegrino P. Myasthenia during interferon alpha therapy. Presse Med 1995; 24: 1178.
34. Mase G, Zorzon M, Biasutti E, Vitrani B, Cazzato G, Urban F, et al. Development of myasthenia gravis during interferon alpha treatment for anti-HCV positive chronic hepatitis. J Neurol Neurosurg Psychiatry 1996; 60: 348-9.
35. Piccolo G, Franciotta D, Versino M, Alfonsi E, Lombardi M, Poma G. Myasthenia gravis in a patient with chronic active hepatitis C during interferon alpha treatment. J Neurol Neurosurg Psychiatry 1996; 60: 348.
36. Triozzi PL, Kinney P, Rinehart JJ. Central nervous system toxicity of biological response modifiers. Ann N Y Acad Sci 1990; 594: 347-54.
37. Meyers CA, Obbens EAMT, Scheibel RS, Moser RP. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 1991; 68: 88-92.
38. Meyers CA, Abbruzzese J. Cognitive functioning in cancer patients: effects of previous treatment. Neurology 1992; 42: 434-6.
39. Laaksonen R, Niiranen A, Ivanainen M, Mattson K, Holsti L, Farkkila M, et al. Dementia-like largely reversible syndrome after cranial irradiation and prolonged interferon treatment. Ann Clin Res 1988; 20: 201-3.
40. Meyers CA, Valentine AD. Neurological and psychiatric adverse effects of immunological therapy. Adverse effects. CNS Drugs 1995; 3: 56-68.
41. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alpha therapy for leukemia. Neurology 1995; 45: 947-50.
42. Calvet MO, Gresser I. Interferon enhances the excitability of cultured neurons. Nature 1979; 278: 558-60.
43. Ho BT, Huo YY, Lu J-G. Opioid-dopamine mechanism in the potentiation of D-amphetamine discrimination by interferon-alpha. Pharmacol Biochem Behav 1992; 42: 57-60.
44. Williams S, Marrero R, Pérez L. Alcoholismo, interferón y perfil lipidico. Modelos experimentales en ratas. Abstract Conference of Interferon and Byotechnology. Nov 28- Dec 3. La Habana, 1992. p. 115.
45. D'Urso R, Falaschi P, Canfalone E, Carusi A, Proietti V, Barnaba F, et al. Neuroendocrine effects of recombinant alpha-IFN administration in humans. Prog Neuroendocrinol Immunol 1991; 4: 20.
46. Saphier D, Welch TE, Chuluyan E. Alpha interferon inhibits adrenocortical secretion via μ-opioid receptors in the rat. Eur J Pharmacol 1993; 238: 183-91.
47. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R. Repeated interferon alfa administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997; 747: 348-51.
48. Birmanns B, Saphier D, Abramsky O. Alpha interferon modifies cortical EEG activity: dose-dependence and antagonism by naloxone. J Neurol Sci 1990; 100: 22-6.
49. Ho B, Huo Y, Lu JG. Opioid-dopaminergic mechanisms in the potentiation of D-amphetamine discrimination by interferon alpha. Pharmacol Biochem Behav 1991; 42: 57-60.
50. Zawada WM, Clarke J, Ruwe WD. Naloxone differentially alters fevers induced by cytokines. Neurochem Int 1997; 30: 441-8.
51. Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. 6 ed. New York: Oxford University Press; 1991.
52. Bocci V. Metabolism of protein anticancer agents. Pharmacol Ther 1987; 34: 1.
53. Bocci V. Pharmacokinetics of interferons and routes of administration in Interferon. Principles and practical applications. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Klimpel GR, et al, eds. Interferon: principles and medical applications. Galveston, Tx: University Texas Med Branch; 1992. p. 417-27.
54. Smith RA, Norris F, Palmer D, Bernhardt L, Wilis RJ. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration. Clin Pharmacol Ther 1985; 37: 85-8.
55. Alam J, McAllister A, Scaramucci J, Jones W, Rogge M. Pharmacokinetics and pharmacodynamics of interferon beta 1a (IFN beta-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration. Clin Drug Invest 1997; 14: 35-43.
56. González-Cabañas R, Rodríguez JL, Valenzuela C, Ducongé J, Castillo R, Ferrero J, et al. Compared pharmacokinetics and side effects after a single intramuscular administration of 2 interferon alfa-2b formulations in healthy volunteers. Avances en Biotecnología Moderna 1997; 4: T2
57. Zhi J, Teller SB, Satoh H, Koss-Twardy GS, Luke DR. Influence of human serum albumin content in formulations on the bioequivalency of interferon alpha-2a given by subcutaneous injection in healthy male volunteers. J Clin Pharmacol 1995; 35: 281-4.
58. Habif DV, Lipton R, Cantell K. Interferon crosses blood-cerebrospinal fluid barrier in monkeys. Proc Soc Exp Biol Med 1975; 149: 287-9.
59. Billiau A, Heremans H, Ververken D, van Damme JV, Carton H, de Sommer P. Tissue distribution of human interferons after exogenous administration in rabbits, monkeys and mice. Arch Virol 1981; 68: 19-25.
60. Smith RA, Landel C, Cornelius CE, Revel M. Mapping the action of interferon on primate brain. In Cantell K, Schellekens H, eds. The Biology of the Interferon System. Boston: Martinas Nijhoff; 1987. p. 563-6.
61. Wiranowska M, Wilson TC, Thompson K, Prockop LD. Cerebral interferon entry in mice after osmotic alteration of blood-brain-barrier. J Interferon Res 1989; 91: 353-62.
62. Pan W, Banks WA, Kastin AJ. Permeability of the blood-brain and the blood-spinal cord barriers to interferons. J Neuroimmunol 1997; 76: 105-11.
63. Marcovist R, Germano PML, Rivieri Y, Tsiang H, Hovanessian AG. The effect of interferon treatment in rabies prophylaxis in immunocompetent, immunosuppressed and immunodeficient mice. J Interferon Res 1987; 7: 117-27.
64. Steiniger B, van der Meide P. Rat ependymoma and microglia cell express Class II-MHC antigens after intravenous infusion of recombinant gamma interferon. J Neuroimmunol 1988; 19: 111-8.
65. Tyring SK. Introduction to clinical use of interferon. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Klimpel GR, et al, eds. Interferon: principles and medical applications. Galveston, Tx: University Texas Med Branch; 1992. p. 399-408.
66. Dianzani F. Biological basis for therapy and for side effects. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Klimpel GR, et al, eds. Interferon: principles and medical applications. Galveston, Tx: University Texas Med Branch; 1992. p. 409-16.
67. López-Saura P, del Rosario M. Interferons in Cuba. What we have and where do we go? Avances en Biotecnología Moderna 1997; 4: T.
68. Limonta M, Ramírez V, López-Saura P, Aguilera A, Pentón E, Barcelona S, et al. Uso del interferon leucocitario durante una epidemia de dengue hemorrágico (virus tipo II) en Cuba. Interferon y Biotecnología 1984; 1: 15-22.
69. Aguilera A, López-Saura P. Uso del Interferon alfa-2 recombinante en la prevención de la conjuntivitis hemorrágica aguda. Biotecnología Aplicada 1990; 7: 197-200.
70. Castañeda-Guillot C, Sotto-Escobar A, López-Saura P. Antiviral effect of interferon: the interferon in viral hepatitis. Rev Roum Virol 1990; 41: 171-9.
71. Arús Soler E, Infante Velázquez M, Padrón GJ, Morales MG, Grá B, López Saura P. Interferón alfa 2b recombinante en hepatitis C crónica. Resultados del tratamiento y determinación de anticuerpos antinterferón. Biotecnología Aplicada 1997; 14: 242-7.
72. Deuñas L, Alcantaud V, Álvarez F, Arteaga J, Benítez A, Bouza M, et al. Use of interferon alpha in laryngeal papillomatosis. Eight years of the national program in Cuba. J Laryngol Otol 1997; 111: 134-40.
73. Rivero J, Limonta M, Aguilera A, Fraga M, López-Saura P. Use of recombinant interferon alpha in human immunodeficiency virus (HIV) infected individuals. Biotherapy 1995; 8: 23-31.
74. Barroso MC, Díaz C, Vázquez E, Asina S, Areces F, Rodríguez O. Evaluación del interferón alfa leucocitario en el mantenimiento de la respuesta en linfomas no Hodgkin. Rev Cub Oncol 1991; 7: 8-12.
75. Martínez E, Miranda N, Garmendía G, Lonchon M, Ward NA, González-Cabaña R, et al. Successful interferon alpha-2b treatment of children with hemangiomas. Avances en Biotecnología Moderna 1997; 4: T32.
76. Coto C, Varela G, Hernández V, del Rosario M, López-Saura P. Use of recombinant interferon gamma in pediatric patients with advanced juvenile chronic arthritis. Aplicaciones modernas de la Biotecnología 1999; 5: T15.
77. Astorga R, de la Cruz M, del Río A, González R, López-Saura P. Intralesional interferon alpha-2b for the treatment of Peyronié's disease. Avances en Biotecnologia Moderna 1997; 4: T32.
78. Greenberg SB. Clinical use of interferons (IFNs) in respiratory and other viral diseases. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Klimpel GR, et al, eds. Interferon: principles and medical applications. Galveston, Tx: University Texas Med Branch; 1992. p. 463-74.
79. Seife R, Cabrera G, Díaz de Villegas E, Castillo MD, Sabatés M, Apolinaire JJ. Uso del interferón alfa leucocitario en el herpes zoster. Biotecnología Aplicada 1990; 7: 301-6.
80. Díaz de la Rocha A, Sagaró B, Selman-Houssein E, Ramírez V, Rodríguez MA, Cortina M. Uso del interferon alfa en el herpes zoster. Interferón y Biotecnología 1988; 5: 47-52.
81. Díaz de la Rocha A, Sagaró B, Selman-Houssein E, Pérez T, Rodríguez MA, Cortina M. Uso del interferón leucocitario humano en el herpes zoster. Reporte de los resultados en 100 casos tratados. Actas Dermo-Sif 1990; 1: 231-3.
82. Salazar AM, Gibbs CJ, Gajdusek DC, Smith RA. Clinical use of interferons: Central Nervous System Disorders. In Came PE, Carter WA eds. Handbook of experimental pharmacology. Berlin: Springer-Verlag; 1984. p. 471-97.
83. Stadler R, Ruszczak Z. Interferons. New additions and indications for use. Dermatologic Clinics 1993; 11: 187-98.
84. Westarp ME, Hulser P-J, Westphal KP, Wolinsky KH, Komhuber HH. Less drug fever with intrathecally applied interferon-beta (short communication). Int J Clin Pharmacol Ther Toxicol 1991; 29: 71-4.
85. Kuroda Y, Kurohara K, Fujiyama F. Systemic IFN alpha in the treatment of HTLV-I associated myelopathy. Acta Neurol Scand 1992; 86: 82-6.
86. Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, et al. Interferon alpha is effective in HTLV-I-associated myelopathy. A multicenter, randomized, double-blind, controlled trial. Neurology 1996; 46: 1016-21.
87. Yamasaki K. Long term high dose IFN alpha treatment in HTLV-I associated myelopathy/tropical spastic paraparesis. A combined clinical, virological and immunological study. J Neurol Sci 1997; 147; 135-44.
88. Anlar B, Yalaz K, Oktem F, Kose G. Long-term follow up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon. Neurology 1997; 48: 526-8.
89. Cianchetti C, Marrosu MG, Muntoni F, Fratta AL, Zuddas A. Intraventricular alfa-interferon in subacute sclerosing panencephalitis. Neurology 1998; 50: 315-6.
90. Tomoda A, Miike T, Miyagawa SH, Negi A, Takeshima H. Subacute sclerosing panencephalitis and chorioretinitis. Brain Develop 1997; 19: 55-7.
91. Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992; 5: 49-73.
92. Huang S, Skolasky RL, Dal Pan G, Royal W, McArthur JC. Survival prolongation and symptom palliation in HIV-seropositive patients with PML treated with alpha interferon. Neurology 1997; 48: A163.
93. Brancacho R, Sardiñas N, Gutiérrez J, González B. Epilepsia parcial continua. Presentación de un caso. Rev Hosp Psiquiat Hab 1988; 29: 79-85.
94. Prusiner SB. Prion biology. In Prusiner SB, Collinge J, Powell J, Anderson B, eds. Prion diseases of humans and animals. New York: Ellis Horwood; 1992. p. 533-67.
95. Wientjens DPWM, Davanipour Z, Hofman A, Kondo K, Matthews WB, Will RG, et al. Risk factors for Creutzfeldt-Jakob disease: a re-analysis of case-control studies. Neurology 1996; 46: 1287-91.
96. Cabrera-Gómez JA, López O, Galarraga J. Encefalopatía espongiforme subaguda (enfermedad de Creulzfeldt-Jakob). Estudio de 3 cases. Rev Hosp Psiq Habana 1983; 24: 153-6.
97. Epstein LG, Brown P. Bovine spongiform encephalopathy and a new variant of Creutzfeldt-Jakob disease. Neurology 1997; 48: 569-71.
98. Chiu HH, Chen RL, Lin KH, Lin KB. Recombinant alpha-interferon treatment of intracranial hemangioma and Kasabach-Merritt syndrome in en infant with cytomegalovirus. J Formos Med Assoc 1995; 94: 261-6.
99. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alpha-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1465-63.
100. Shenoy M, Baron S, Wu B, Goluzko E, Christadoss P. IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis. J Immunol 1995; 154: 6203-8.
101. Wang ZY, Link H, Ljundahl A, Hojeberg B, Link J, He B, et al. Induction of interferon-gamma, interleukin 4 and transforming growth factor-beta in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell Immunol 1994; 157: 353-68.
102. Gu D, Wogensen L, Calcutt NA, Xia C, Zhu S, Merlie JP, et al. Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction. J Exp Med 1995; 181: 547-57.
103. Link H, Xu ZY, Melms P, Kalbacher H, Sun JB, Wang ZY, et al. The T-cell repertoire in myasthenia gravis involves multiple cholinergic receptor epilopes. Scand J Immunol 1992; 36: 405-14.
104. Pérez A, Perella M, Pastor E, Cano M, Escudero J. Myasthenia gravis induced by alpha interferon therapy. Am J Hematol 1995; 49: 365-6.
105. Gorson KC, Allam G, Simovic D, Ropper AH. Improvement following interferon-alpha 2a in chronic inflammatory demyelinating polyneuropathy. Neurology 1997; 48: 777-80.
106. Gorson KC, Ropper AH, Clark BD, Dew RB, Simovic D, Allam G. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998; 50: 84-7.
107. Fleischmann WR Jr. Viral infection and interferons. In McKendall RR, Stroop WG, eds. Handbook of Neurovirology. New York: Marcel Dekker; 1994. p. 75-86.
108. Migliaresi S, Tirri G. Interferon in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13 (Suppl): 175-80.
109. Khella SL, Frost S, Hermann GA. Hepatitis C infection, cryoglobulinemia and vasculitic neuropathy. Treatment with interferon alpha: a case report and literature review. Neurology 1995; 45: 407-11.
110. Apartis E, Leger JM, Musset L, Gugenheim M, Cacoub P, Lyon-Caen O, et al. Peripheral neuropathy associated with essential mixed cryoglobulinemia: a role for hepatitis C virus infection? J Neurol Neurosurg Psychiatry 1996; 60: 661-6.
111. Ghin M, Mascia MT, Gentilini M, Mussini C. Treatment of cryoglobulinemic neuropathy with alpha interferon. [Letter]. Neurology 1996; 46: 588-9.
112. Leger JM, Mariette X, Chastange E, Clavelou P, Loubortin JP, Bouche P, et al. A randomized trial comparing alpha-IFN and intravenous immunoglobulin in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 1996; 46: A-380.
113. Strander H, Oberg K. Clinical use of IFNs: solid tumors. In Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK, Klimpel GR, et al, eds. Interferon: principles and medical applications. Galveston. Tx: University Texas Med Branch; 1992. p. 533-61.
114. Pereira R, Dolorit F, Izquierdo P, Gallardo R, Dejohng L, Ramírez V. Interferón y gliomas encefálicos. Primer grupo de tratamiento. Rev Cub Cirugía 1987; 26: 34-43.
115. Perea S, Gerónimo H, López-Saura P. Expresión de receptores para el interferón alfa en líneas celulares procedentes de tumores humanos. Relación con el efecto antiproliferativo. Acta Científica Venezolana 1993; 44: 22-7.
116. Olopade OI, Jenkins RB, Ransom DT, Malik K, Pomykala H, Nobori T, et al. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res 1992; 52: 2523-9.
117. Ichimura K, Schmidt EE, Yamaguchi N, James CD, Collins VP. A common region of homozygous deletion in malignant human gliomas lies between the IFN alpha/omega gene cluster and the D9S171 locus. Cancer Res 1994; 54: 3127-30.
118. Zhang W, Hara A, Murakawa T, Niikawa S, Andoh T, et al. Effect of interferon-gamma on ACNU-induced DNA damage and cytotoxicity in human glioblastoma cells. Neurol Med Chir Tokyo 1993; 33: 275-9.
119. Merchant RE, McVicer DW, Merchant LH, Young HF. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial. J Neurooncol 1992; 12: 75-83.
120. Salmaggi A, Dufour A, Silvani A, Ciusani E, Nospolo A, Boiardi A. Immunological fluctuations during intrathecal immunotherapy in three patients affected by CNS tumours disseminating via CSF. Int J Neurosci 1994; 7: 117-25.
121. Jereb B, Petric-Grabnar G, Klun B, Lamovec J, Skreb M, Soos E. Addition of IFN alpha to treatment of malignant brain tumors. Acta Oncol 1994; 33: 651-4.
122. Färkkila M, Jaaskelainen J, Kallio M, Blomstedt G, Raininko R, Virkkunen P, et al. Randomized, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. Br J Cancer 1994; 70: 138-41.
123. Buckner JC, Brown LD, Kugler JW, Cascino TL, Krook JE, Mailliard JA, et al. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 1995; 82: 430-5.
124. Dillman RO, Weimann M, Oldham RK, Soori G, Bury M, Hafer R, et al. Interferon alpha-2A and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group. Cancer Biother 1995; 10: 265-71.
125. Yoshida J, Yagi K. Basic study on liposome-mediated interferon gene therapy of human brain tumors. J Interferon Res 1993; 13 (Suppl 1): S208.
126. Tanaka S, Okada M, Murakami M, Hirakawa M, Manaka S, Nagashima T. Human interferon-beta therapy for cerebral primitive neuroectodermal tumors: two case reports. Neurol Med Chir Tokyo 1995; 35: 82-6.
127. Packer RJ, Prados M, Phillips P, Nicholson HS, Boyett JM, Goldwein J, et al. Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a children cancer group phase I/II study. Cancer 1996; 77: 2150-6.
128. Kaba S, DeMonte F, Bruner J, Kyritsis A, Jaeckle K, Levin V, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2b. Neurosurgery 1997; 40: 271-5.
129. Thompson JA, Gold PJ, Fefer A. Outpatient chemo-immunotherapy for the treatment of metastatic melanoma. Semin Oncol 1997; 24(Suppl 4): S4-44, S4-48.
130. Phuphanich S, Jacobs M, Spiers A. Response of recurrent brain metastases in malignant melanoma to 5-fluoracil and interferon alpha therapy. J Neuroimaging 1994; 4: 114-6.
131. Salpietro FM, Cipri S, Alafaci C, Tripodi M, Alonci A, Buda G, et al. Combined systemic beta interferon and thymostimulin administration for metastatic brain tumors. A brief report. J Neurosurg Sci 1994; 38: 35-42.
132. Pérez-Lache N. Cuadro clínico y fisiopatología de la forma periférica de la neuropatía epidémica en Cuba, 1992-1994. La Habana: Ciencias Médicas; 1995. p. 45-56.
133. Cabrera-Gómez JA, Collazo H, García L, Grupo Cooperativo para el Tratamiento de la Neuropatía Epidémica. Características clínicas de la neuropatía epidémica, forma periférica, en la provincia de Cienfuegos. Rev Neurol 1997; 25: 1852-8.
134. Pérez Cristiá R, Fleites P. Análisis y discusión de la hipótesis tóxico-nutricional como posible causa de la neuropatía epidémica. Neuropatía epidémica en Cuba, 1992-1994. La Habana: Ciencias Médicas; 1995. p. 117-58.
135. Espinosa A, Ordúñez P. Nuevas reflexiones sobre las determinantes de la epidemia de neuropatía en Cuba. Rev Finlay 1993; 7: 1-103.
136. Resultado de las investigaciones virológicas en pacientes con neuropatía epidémica. Neuropatía epidémica en Cuba 1992-1994. La Habana: Ciencias Médicas; 1995. p. 169-86.
137. González P, Tula L, Rodríguez M, Céspedes A, Martínez J, Pascual MA, et al. Estudio clínico-terapéutico controlado y multicéntrico en pacientes con neuropatía epidémica en su forma óptica. Neuropatía epidémica en Cuba, 1992-1994. La Habana: Ciencias Médicas; 1995. p. 187-217.
138. López Saura P, Hernández F, González T, Labarta V, Valdés RA, Sáez V, et al, and Cuban multicenter group for clinical trials with interferon in epidemic neuropathy. Interferon alpha-2b in epidemic neuropathy. Biotecnología Aplicada 1995; 12: 188-9.
139. Hernández F, Labarta V, Valdés RA, Sáez V, Morlans A, Guerra M, et al. Uso de interferon alfa-2b recombinante en neuropatía epidémica. Prueba terapéutica. Pinar del Río. Biotecnología Aplicada 1995; 12: 189-90.
140. Hernández F, Labarta V, Valdés RA, Sáez V, Morlans A, Vera H, et al. Uso de distintas dosis de interferon alfa-2b recombinante en el tratamiento de la neuropatía epidémica. Biotecnología Aplicada 1995; 12: 190-1.
141. Hernández F, Labarta V, Valdés RA, Sáez V, Morlans A, Luis S, et al. Interferon alpha-2b and hydroxocobalamine in epidemic neuropathy. Biotecnología Aplicada 1995; 12: 191-2.
142. Hernández F, Labarta V, Valdés RA, Sáez V, Morlans A, Ruiz F, et al. Interferón alfa-2b recombinante o hidroxocobalamina en el tratamiento de la neuropatía epidémica. Santiago de Cuba. Biotecnología Aplicada 1995; 12: 198.
143. Cabrera-Gómez JA, Collazo H, Díaz M, García J. The most severe cases of Epidemic Neuropathy in Cienfuegos, Cuba. J Neurol Sci 1997; 150: S308.